Pharmacyclics completes Phase II Xcytrin enrollment

PCYC completed enrollment of 24 patients with newly diagnosed glioblastoma multiforme in a single-arm Phase II trial of its Xcytrin motexafin gadolinium radiosensitizer. The trial will assess safety a...